Skip to main content
Have a personal or library account? Click to login
The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review Cover

The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review

Open Access
|Sep 2026

References

  1. Cancer Factsheets in EU-27 countries - 2020 | ECIS - European Cancer Information System [Internet]. [cited 2023 Nov 12]. Available at: https://ecis.jrc.ec.europa.eu/cancer-factsheets-eu-27-countries-2020
  2. Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 327: 1479-82. doi: 10.1016/S0140-6736(86)91510-2
  3. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative Versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 Randomized Phase III Trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33. doi: 10.1200/JCO.2011.40.1836
  4. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-50. doi: 10.1200/JCO.2005.08.144
  5. Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 Trial. Ann Oncol 2024; 35: 873-81. doi: 10.1016/j.annonc.2024.06.019
  6. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2022; 8: e215445. doi: 10.1001/jamaoncol.2021.5445
  7. Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019; 30: 1298-303. doi: 10.1093/annonc/mdz186
  8. Li H, Tang Y, Zhou H, Hu C, Wei L, Zhang Y, et al. Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a Randomized Phase II/III Trial (STELLAR II study). Int J Radiat Oncol Biol Phys 2024; 120: e462. doi: 10.1016/j.ijrobp.2024.07.1025
  9. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO Trial. Ann Surg 2023; 278: e766-72. doi: 10.1097/SLA.0000000000005799
  10. Rokan Z, Simillis C, Kontovounisios C, Moran B, Tekkis P, Brown G. Locally recurrent rectal cancer according to a Standardized MRI Classification System: a systematic review of the literature. J Clin Med 2022; 11: 3511. doi: 10.3390/jcm11123511
  11. Bhangu A, Ali SM, Darzi A, Brown G, Tekkis P. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. Colorectal Dis 2012; 14: 1457-66. doi: 10.1111/j.1463-1318.2012.03005.x
  12. Bhangu A, Ali M, Cunningham D, Brown G, Tekkis PP. Comparison of longterm survival outcomes of operative versus nonoperative management of recurrent rectal cancer. J Clin Oncol 2012; 30: e14132. doi: 10.1200/jco.2012.30.15_suppl.e14132
  13. Hagemans JAW, Van Rees JM, Alberda WJ, Rothbarth J, Nuyttens JJME, Van Meerten E, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol 2020; 46: 448-54. doi: 10.1016/j.ejso.2019.10.037
  14. Bird TG, Ngan SY, Chu J, Kroon R, Lynch AC, Heriot AG. Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent. Int J Colorectal Dis 2018; 33: 393-401. doi: 10.1007/s00384-018-2985-y
  15. Zhao J. Patterns and prognosis of locally recurrent rectal cancer following multidisciplinary treatment. World J Gastroenterol 2012; 18: 7015. doi: 10.3748/wjg.v18.i47.7015
  16. Yamada K, Ishizawa T, Niwa K, Chuman Y, Akiba S, Aikou T. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg 2001; 88: 988-93. doi: 10.1046/j.0007-1323.2001.01811.x
  17. Moore HG, Shoup M, Riedel E, Minsky BD, Alektiar KM, Ercolani M, et al. Colorectal cancer pelvic recurrences: determinants of resectability. dis colon rectum 2004; 47: 1599-606. doi: 10.1007/s10350-004-0677-x
  18. Gao Z, Gu J. Surgical treatment of locally recurrent rectal cancer: a narrative review. Ann Transl Med 2021; 9: 1026. doi: 10.21037/atm-21-2298
  19. Fahy MR, Hayes C, Kelly ME, Winter DC. Updated systematic review of the approach to pelvic exenteration for locally advanced primary rectal cancer. Eur J Surg Oncol 2022; 48: 2284-91. doi: 10.1016/j.ejso.2021.12.471
  20. Platt E, Dovell G, Smolarek S. Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer. Tech Coloproctol 2018; 22: 835-45. doi: 10.1007/s10151-018-1883-1
  21. Beyond TME Collaborative; Ali SM, Antoniou A, Beynon J, Bhangu A, Bose P, et al. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 2013; 100: 1009-14. doi: 10.1002/bjs.9192
  22. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv22-40. doi: 10.1093/annonc/mdx224
  23. Piqeur F, Creemers DMJ, Banken E, Coolen L, Tanis PJ, Maas M, et al. Dutch national guidelines for locally recurrent rectal cancer. Cancer Treat Rev 2024; 127: 102736. doi: 10.1016/j.ctrv.2024.102736
  24. Enríquez-Navascués JM. Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol 2011; 17: 1674. doi: 10.3748/wjg.v17.i13.1674
  25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; n71. doi: 10.1136/bmj.n71
  26. Habermehl D, Wagner M, Ellerbrock M, Büchler MW, Jäkel O, Debus J, et al. Reirradiation using carbon ions in patients with locally recurrent rectal cancer at HIT: first results. Ann Surg Oncol 2015; 22: 2068-74. doi: 10.1245/s10434-014-4219-z
  27. Moningi S, Ludmir EB, Polamraju P, Williamson T, Melkun MM, Herman JD, et al. Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol 2019; 19: 59-65. doi: 10.1016/j.ctro.2019.08.004
  28. Shirai K, Ohno T, Saitoh J ichi, Okamoto M, Katoh H, Murata K, et al. Prospective study of isolated recurrent tumor re-irradiation with carbon-ion beams. Front Oncol 2019; 9: 181. doi: 10.3389/fonc.2019.00181
  29. Bird TG, Ngan SY, Chu J, Kroon R, Lynch AC, Heriot AG. Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent. Int J Colorectal Dis 2018; 33: 393-401. doi: 10.1007/s00384-018-2985-y
  30. Tang Z, Liu L, Liu D, Wu L, Lu K, Zhou N, et al. Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer. Cancer Manag Res 2020; 12: 12277-86. doi: 10.2147/CMAR.S278427
  31. Al-Haidari G, Skovlund E, Undseth C, Rekstad BL, Larsen SG, Åsli LM, et al. Re-irradiation for recurrent rectal cancer - a single-center experience. Acta Oncol 2020; 59: 534-40. doi: 10.1080/0284186X.2020.1725111
  32. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, Martijn H, Creemers GJ, Rutten HJT. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg 2014; 101: 1280-9. doi: 10.1002/bjs.9569
  33. Cai G, Zhu J, Palmer JD, Xu Y, Hu W, Gu W, et al. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. Radiat Oncol 2015; 10: 57. doi: 10.1186/s13014-015-0360-5
  34. Chung SY, Koom WS, Keum KC, Chang JS, Shin SJ, Ahn JB, et al. Treatment outcomes of re-irradiation in locoregionally recurrent rectal cancer and clinical significance of proper patient selection. Front Oncol 2019; 9: 529. doi: 10.3389/fonc.2019.00529
  35. Jo S, Choi Y, Park SK, Kim JY, Kim HJ, Lee YH, et al. Efficacy of dose-escalated radiotherapy for recurrent colorectal cancer. Ann Coloproctol 2016; 32: 66. doi: 10.3393/ac.2016.32.2.66
  36. Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, et al. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br J Radiol 2017; 90: 20170134. doi: 10.1259/bjr.20170134
  37. Park Y, Kim K, Park HJ, Jeong SY, Park KJ, Han SW, et al. Results of re-irradiation for pelvic recurrence in anorectal cancer patients. Br J Radiol 2019; 92: 20180794. doi: 10.1259/bjr.20180794
  38. Sun DS, Zhang JD, Li L, Dai Y, Yu JM, Shao ZY. Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 2012; 85: 259-64. doi: 10.1259/bjr/28173562
  39. Susko M, Lee J, Salama J, Thomas S, Uronis H, Hsu D, et al. The use of reirradiation in locally recurrent, non-metastatic rectal cancer. Ann Surg Oncol 2016; 23: 3609-15. doi: 10.1245/s10434-016-5250-z
  40. Tanaka H, Yamaguchi T, Hachiya K, Okada S, Kitahara M, Matsuyama K, et al. Radiotherapy for locally recurrent rectal cancer treated with surgery alone as the initial treatment. Radiat Oncol J 2017; 35: 71-7. doi: 10.3857/roj.2016.02005
  41. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, et al. Hyperfractionated accelerated reirradiation for rectal cancer: an analysis of outcomes and toxicity. Radiother Oncol 2017; 122: 146-51. doi: 10.1016/j.radonc.2016.12.015
  42. Watanabe J, Shoji H, Hamaguchi T, Miyamoto T, Hirano H, Iwasa S, et al. Chemoradiotherapy for local recurrence of rectal cancer: a single center study of 18 patients. In Vivo 2019; 33: 1363-8. doi: 10.21873/invivo.11612
  43. Youssef FF, Parikh PJ, DeWees TA, Mutch MG, Tan BR, Grigsby PW, et al. Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy. Adv Radiat Oncol 2016; 1: 94-100. doi: 10.1016/j.adro.2016.02.002
  44. Koom WS, Choi Y, Shim SJ, Cha J, Seong J, Kim NK, et al. Reirradiation to the pelvis for recurrent rectal cancer. J Surg Oncol 2012; 105: 637-42. doi: 10.1002/jso.23023
  45. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010; 77: 60-5. doi: 10.1016/j.ijrobp.2009.04.056
  46. Cai G, Zhu J, Hu W, Zhang Z. Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. Radiat Oncol 2014; 9: 278. doi: 10.1186/s13014-014-0278-3
  47. Holman FA, Bosman SJ, Haddock MG, Gunderson LL, Kusters M, Nieuwenhuijzen GAP, et al. Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer. Eur J Surg Oncol 2017; 43: 107-17. doi: 10.1016/j.ejso.2016.08.015
  48. Dagoglu N, Mahadevan A, Nedea E, Poylin V, Nagle D. Stereotactic body radiotherapy (SBRT) reirradiation for pelvic recurrence from colorectal cancer. J Surg Oncol 2015; 111: 478-82. doi: 10.1002/jso.23858
  49. DeFoe S, Bernard M, Rwigema JC, Heron D, Ozhasoglu C, Burton S. Stereotactic body radiotherapy for the treatment of presacral recurrences from rectal cancers. J Can Res Ther 2011; 7: 408. doi: 10.4103/09731482.92000
  50. Johnstone P, Okonta L, Aitken K, Holmes J, Harrison M, Harji D, et al. A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence. Radiother Oncol 2021; 162: 1-6. doi: 10.1016/j.radonc.2021.06.030
  51. Kim MS, Choi C, Yoo S, Cho C, Seo Y, Ji Y, et al. Stereotactic Body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol 2008; 38: 695-700. doi: 10.1093/jjco/hyn083
  52. Minneci M, Baclay JRM, Von Eyben R, Vitzthum L, Pollom E, Chang DT. The utility of stereotactic body radiotherapy for pelvic recurrences after prior radiation therapy. Int J Radiat Oncol Biol Phys 2021; 111: e59-60. doi: 10.1016/j.ijrobp.2021.07.405
  53. Smith T, O’Cathail SM, Silverman S, Robinson M, Tsang Y, Harrison M, et al. Stereotactic body radiation therapy reirradiation for locally recurrent rectal cancer: outcomes and toxicity. Adv Radiat Oncol 2020; 5: 1311-9. doi: 10.1016/j.adro.2020.07.017
  54. Yamada S, Kamada T, Ebner DK, Shinoto M, Terashima K, Isozaki Y, et al. Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys 2016; 96: 93-101. doi: 10.1016/j.ijrobp.2016.04.022
  55. Yamada S, Takiyama H, Isozaki Y, Shinoto M, Ebner DK, Koto M, et al. Carbon ion radiotherapy for locally recurrent rectal cancer of patients with prior pelvic irradiation. Ann Surg Oncol 2022; 29: 99-106. doi: 10.1245/s10434-021-10876-4
  56. Takagawa Y, Suzuki M, Seto I, Azami Y, Machida M, Takayama K, et al. Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation. J Radiat Res 2024; 65: 379-86. doi: 10.1093/jrr/rrae019
  57. Takagawa Y, Suzuki M, Yamaguchi H, Seto I, Azami Y, Machida M, et al. Outcomes and prognostic factors for locally recurrent rectal cancer treated with proton beam therapy. Adv Radiat Oncol 2023; 8: 101192. doi: 10.1016/j.adro.2023.101192
  58. Shinoto M, Yamada S, Okamoto M, Shioyama Y, Ohno T, Nakano T, et al. Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. Radiother Oncol 2019; 132: 236-40. doi: 10.1016/j.radonc.2018.10.007
  59. Shiba S, Okamoto M, Shibuya K, Kobayashi D, Miyasaka Y, Ohno T. Five-year outcomes in carbon-ion radiotherapy for postoperative pelvic recurrence of rectal cancer: a prospective clinical trial (GUNMA 0801). Clin Transl Radiat Oncol 2024; 44: 100701. doi: 10.1016/j.ctro.2023.100701
  60. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Bafford A, Jiang Y, et al. Reirradiation for rectal cancer using pencil beam scanning proton therapy: a single institutional experience. Adv Radiat Oncol 2021; 6: 100595. doi: 10.1016/j.adro.2020.10.008
  61. Jeans EB, Ebner DK, Takiyama H, Qualls K, Cunningham DA, Waddle MR, et al. Comparing oncologic outcomes and toxicity for combined modality therapy vs. carbon-ion radiotherapy for previously irradiated locally recurrent rectal cancer. Cancers 2023; 15: 3057. doi: 10.3390/cancers15113057
  62. Hiroshima Y, Ishikawa H, Murakami M, Nakamura M, Shimizu S, Enomoto T, et al. Proton beam therapy for local recurrence of rectal cancer. Anticancer Res 2021; 41: 3589-95. doi: 10.21873/anticanres.15147
  63. Chung SY, Takiyama H, Kang JH, Chang JS, Min BS, Tsuji H, et al. Comparison of clinical outcomes between carbon ion radiotherapy and X-ray radiotherapy for reirradiation in locoregional recurrence of rectal cancer. Sci Rep 2022; 12: 1845. doi: 10.1038/s41598-022-05809-4
  64. Cai X, Du Y, Wang Z, Li P, Yu Z, Zhang Q, et al. The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience. Radiat Oncol 2020; 15: 209. doi: 10.1186/s13014-020-01653-w
  65. Cai X, Li P, Zhao J, Wang W, Cheng J, Zhang G, et al. Definitive carbon ion re-irradiation with pencil beam scanning in the treatment of unresectable locally recurrent rectal cancer. J Radiat Res 2023; 64: 933-9. doi: 10.1093/jrr/rrad068
  66. Barcellini A, Vitolo V, Cobianchi L, Peloso A, Vanoli A, Mirandola A, et al. Reirradiation with carbon ion radiotherapy for pelvic rectal cancer recurrences in patients previously irradiated to the pelvis. In Vivo 2020; 34: 1547-53. doi: 10.21873/invivo.11944
  67. Hamauchi S, Yamazaki K, Yasui H, Boku N, Onozawa Y, Fukutomi A, et al. Safety and efficacy of proton-beam radiation therapy for patients with locally recurrent rectal cancer. Ann Oncology 2012; 23: xi160. doi: 10.1016/S0923-7534(20)32506-0
  68. Shiba S, Okamoto M, Kiyohara H, Ohno T, Kaminuma T, Asao T, et al. Prospective observational study of high-dose carbon-ion radiotherapy for pelvic recurrence of rectal cancer (GUNMA 0801). Front Oncol 2019; 9: 702. doi: 10.3389/fonc.2019.00702
  69. Shioyama Y. A phase II clinical trial of carbon-ion radiotherapy for patients with local recurrence after primarily resected rectal cancer (HIMAT1351) [Internet]. Clinical trial registration. [cited 2025 Sep 13]. Available at: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&language=J&recptno=R000015979
  70. Yamada S. A phase II clinical trial of carbon-ion radiotherapy for pelvic recurrent rectal cancer in patients with prior pelvic carbon-ion irradiation. [Internet]. UMIN Clinical Trials Registry U. [cited 2025 Sep 13]. Available at: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025839
  71. Cai X. A Prospective Phase II clinical study of carbon ion re-irradiation in unresectable locally recurrent rectal cancer [Internet]. [Clinical trial registration] clinicaltrials.gov; 2023 [cited 2025 Sep 13]. Available at: https://clinicaltrials.gov/study/NCT05807984
  72. Wan J, Wu R, Fu M, Shen L, Zhang H, Wang Y, et al. TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial. Front Oncol 2023; 13: 1304767. doi: 10.3389/fonc.2023.1304767
  73. Kim HC. Concurrent chemo-proton radiotherapy with or without resection and spacer insertion for loco-regional recurrence of previous irradiated rectal cancer (RECCPT) [Internet]. [cited 2025 Sep 14]. Available at: https://clinicaltrials.gov/study/NCT03098108.clinicaltrials.gov; 2018.
  74. Washington University School of Medicine. Hypofractionated pencil-beam scanning intensity-modulated proton therapy (IMPT) in recurrent rectal cancer (IMPARC) [Internet]. [cited 2025 Sep 14]. Available at: https://clini-caltrials.gov/study/NCT04827732.2025.
  75. Truelsen CG, Rønde HS, Kallehauge JF, Szpejewska JE, Bahij R, Diness LV, et al. Acute toxicity and quality of life in dose-escalated proton reirradiation for locally recurrent rectal cancer: the prospective ReRad II trial. Clin Transl Radiat Oncol 2025; 54: 100999. doi: 10.1016/j.ctro.2025.100999
  76. Gambacorta MA, Romano A, Caravatta L, Macchia G, Chiloiro G, Galofaro E, et al. Radiotherapy & total neoadjuvant therapy for recurrent rectal cancer in previously irradiated patients, (RETRY): a multicenter prospective observational study. Radiat Oncol 2024; 19: 174. doi: 10.1186/s13014-024-02555-x
  77. Denost Q, Frison E, Salut C, Sitta R, Rullier A, Harji D, et al. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer – GRECCAR 15 trial protocol. Colorectal Dis 2021; 23: 1909-18. doi: 10.1111/codi.15670
  78. Combs SE, Kieser M, Habermehl D, Weitz J, Jäger D, Fossati P, et al. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer 2012; 12: 137. doi: 10.1186/1471-2407-12-137
  79. Peterson J, Niles C, Patel A, Boujaoude Z, Abouzgheib W, Goldsmith B, et al. Stereotactic body radiotherapy for large (> 5 cm) non–small-cell lung cancer. Clin Lung Cancer 2017; 18: 396-400. doi: 10.1016/j.cllc.2016.11.020
  80. Dawson LA, Hashem S, Bujold A. Stereotactic body radiation therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2012; 32: 261-4. doi: 10.14694/EdBook_AM.2012.32.171
  81. Shiba S, Okamoto M, Shibuya K, Okazaki S, Miyasaka Y, Ohtaka T, et al. Carbon Ion radiation therapy for postoperative pelvic recurrence of rectal cancer with a large tumor infiltrating and compressing the rectum: a case report. Adv Radiat Oncol 2021; 6: 100774. doi: 10.1016/j.adro.2021.100774
  82. Nagata K, Takiyama H, Tashiro K, Yamadera M, Okamoto K, Kajiwara Y, et al. Multidisciplinary management of locally recurrent rectal cancer with carbon ion radiotherapy followed by prophylactic removal of the irradiated bowel: a case report. Surg Case Rep 2024; 10: 13. doi: 10.1186/s40792-024-01811-2
  83. Kobayashi T, Sekimoto M, Miki H, Yamamoto N, Harino T, Yagyu T, et al. Laparoscopic polyglycolic acid spacer placement for locally recurrent rectal cancer. Colorectal Dis 2024; 26: 760-5. doi: 10.1111/codi.16882
  84. Sasaki R, Demizu Y, Yamashita T, Komatsu S, Akasaka H, Miyawaki D, et al. First-In-human phase 1 study of a Nonwoven Fabric Bioabsorbable Spacer for Particle Therapy: Space-Making Particle Therapy (SMPT). Adv Radiat Oncol 2019; 4: 729-37. doi: 10.1016/j.adro.2019.05.002
  85. Trifiletti DM, Garda AE, Showalter TN. Implanted spacer approaches for pelvic radiation therapy. Expert Rev Med Devices 2016; 13: 633-40. doi: 10.1080/17434440.2016.1195682
DOI: https://doi.org/10.2478/raon-2026-0036 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 323 - 331
Submitted on: Nov 25, 2025
Accepted on: May 22, 2026
Published on: Sep 7, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Ana Perpar, Petra Georg, Ajra Secerov Ermenc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.